

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.8	102.8	(44.3-202.5)	Male	3	5.0	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	5	4.0	124.3	(40.1-290.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.4	134.9	(49.2-293.6)
Female	25	32.0	78.2	(50.6-115.4)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	12.2	131.4	(75.1-213.5)	Female	3	3.3	nc	(nc-nc)
Female	7	9.9	70.8	(28.4-145.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.3	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	33.5	104.6	(72.9-145.5)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	6	6.6	91.1	(33.3-198.3)
Female	4	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	111	111.9	99.2	(81.6-119.4)
Male	2	1.9	nc	(nc-nc)	Female	80	99.4	80.5	(63.8-100.2)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	15.0	107.0	(61.1-173.8)					
Female	10	12.7	78.9	(37.8-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

111
Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	24.8	92.6	(58.7-139.0)	Male	8	13.7	58.5	(25.2-115.2)
Female	7	9.1	77.2	(30.9-159.1)	Female	2	10.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.7	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	Female	5	2.9	174.9	(56.4-408.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.7	nc	(nc-nc)	Male	11	12.6	87.0	(43.4-155.6)
Female	92	82.4	111.6	(90.0-136.9)	Female	7	11.3	61.8	(24.8-127.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	8	8.9	90.3	(38.9-178.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	36.8	84.3	(57.3-119.7)	Female	11	9.1	121.3	(60.5-217.0)
Female	24	36.4	66.0	(42.3-98.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.9	144.6	(69.2-265.9)
Male	3	6.1	nc	(nc-nc)	Female	6	7.8	77.1	(28.1-167.7)
Female	2	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	92.1	85.8	(67.9-107.0)
Male	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	4.0	nc	(nc-nc)
Male	12	10.1	119.1	(61.5-208.1)	<u>Testis</u>				
Female	3	6.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.9	126.7	(40.8-295.6)	Male	1	2.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	7	8.2	85.4	(34.2-176.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.8	89.8	(36.0-185.0)	Female	15	16.9	89.0	(49.8-146.7)
Female	3	6.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	284	321.1	88.4	(78.5-99.4)
Male	3	4.9	nc	(nc-nc)	Female	252	293.2	85.9	(75.7-97.2)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	45.4	101.2	(74.1-135.0)					
Female	39	41.3	94.3	(67.1-128.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

112

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.6	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	6	3.5	171.9	(62.8-374.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.8	159.5	(58.2-347.1)
Female	27	27.5	98.0	(64.6-142.7)	Female	4	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	10.3	116.7	(60.2-203.9)	Female	3	2.9	nc	(nc-nc)
Female	9	9.0	100.1	(45.7-190.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	1.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	1	3.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.2	nc	(nc-nc)	Female	5	5.5	90.1	(29.0-210.3)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.3	nc	(nc-nc)	Male	106	94.1	112.6	(92.2-136.2)
Female	1	1.8	nc	(nc-nc)	Female	81	87.2	92.9	(73.8-115.5)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	1.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	12.6	142.4	(84.3-225.0)					
Female	10	11.2	89.7	(42.9-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

113

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	8	5.9	136.3	(58.7-268.6)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.9	84.5	(27.2-197.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	1	0.3	nc	(nc-nc)	Male	15	20.7	72.5	(40.6-119.6)
Female	0	0.1	nc	(nc-nc)	Female	19	19.0	100.2	(60.3-156.5)
<u>Leukemia</u>					<u>Male</u>				
Male	0	0.5	nc	(nc-nc)	<u>Female</u>				
Female	0	0.4	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	0	0.3	nc	(nc-nc)	<u>Male</u>				
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	0	2.8	nc	(nc-nc)	<u>Female</u>				
Female	3	2.5	nc	(nc-nc)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

114

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	36.4	112.6	(80.8-152.7)	Male	18	20.3	88.7	(52.5-140.1)
Female	14	13.9	100.8	(55.1-169.2)	Female	15	16.9	89.0	(49.8-146.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.9	72.9	(23.5-170.1)	Male	5	5.5	90.5	(29.2-211.2)
Female	8	5.8	138.2	(59.5-272.4)	Female	5	4.4	113.7	(36.6-265.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	24	18.6	129.3	(82.8-192.4)
Female	128	137.6	93.0	(77.6-110.6)	Female	12	17.6	68.2	(35.2-119.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.0	83.8	(27.0-195.5)	Male	18	13.9	129.2	(76.5-204.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	50	54.5	91.7	(68.0-120.9)	Female	9	14.9	60.5	(27.6-114.9)
Female	63	54.8	114.9	(88.3-147.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	10.4	164.2	(95.6-262.9)
Male	9	9.4	95.9	(43.7-182.0)	Female	12	11.8	102.0	(52.7-178.3)
Female	1	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	145	145.3	99.8	(84.2-117.4)
Male	5	2.7	186.7	(60.2-435.8)	<u>Stomach</u>				
Female	6	2.3	266.4	(97.3-579.8)	Male	8	9.2	86.8	(37.4-171.0)
<u>Kidney & Renal Pelvis</u>					Female	7	5.9	118.7	(47.6-244.6)
Male	13	15.5	84.1	(44.7-143.8)	<u>Testis</u>				
Female	12	9.9	120.9	(62.4-211.2)	Male	6	4.5	133.6	(48.8-290.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	6.1	114.2	(45.8-235.3)	Male	5	4.3	117.6	(37.9-274.4)
Female	2	1.8	nc	(nc-nc)	Female	19	13.8	138.0	(83.1-215.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	11.3	123.7	(67.6-207.6)	Female	27	28.6	94.3	(62.1-137.1)
Female	6	9.6	62.3	(22.7-135.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	525	485.2	108.2	(99.1-117.9)
Male	9	7.6	118.9	(54.2-225.7)					
Female	2	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	76	68.4	111.1	(87.6-139.1)					

Female 72 65.4 110.0 (86.1-138.6)

Female 468 468.9 99.8 (91.0-109.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

115

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	4.6	109.1	(35.2-254.6)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

Lung and Bronchus

Male	0	2.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)

All Sites / Types

Male	12	15.0	79.8	(41.2-139.4)
Female	7	12.5	55.8	(22.4-115.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

116
Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	0.0	nc	(nc-nc)					
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

117

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	14.3	84.0	(43.3-146.7)	Male	10	8.6	116.7	(55.9-214.6)
Female	8	5.2	154.0	(66.3-303.5)	Female	9	7.4	121.4	(55.4-230.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.8	77.1	(28.2-167.9)
Female	73	57.1	127.8	(100.1-160.6)	Female	8	7.0	114.3	(49.2-225.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	21.7	101.2	(63.4-153.2)	Female	5	6.1	82.0	(26.4-191.3)
Female	22	20.5	107.6	(67.4-162.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.1	121.8	(39.2-284.2)
Male	4	3.7	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	57.0	75.5	(54.6-101.7)
Male	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.2	nc	(nc-nc)
Male	7	6.4	110.0	(44.1-226.7)	<u>Testis</u>				
Female	4	4.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
<u>Leukemia</u>									
Male	4	4.8	nc	(nc-nc)					

Female	2	3.9	nc	(nc-nc)	Female	6	6.7	89.2	(32.6-194.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	11	11.7	93.9	(46.8-167.9)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male	168	195.5	85.9	(73.4-100.0)
Male	30	27.0	111.1	(74.9-158.6)	Female	197	188.8	104.3	(90.3-120.0)
Female	22	25.2	87.1	(54.6-131.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

118

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.5	92.9	(33.9-202.2)	Male	3	3.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	29	24.0	120.7	(80.8-173.3)	Female	1	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	6	2.6	226.7	(82.8-493.4)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	6	9.8	61.1	(22.3-132.9)	<u>Ovary</u>				
Female	10	8.2	121.9	(58.4-224.2)	Female	0	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	25	26.7	93.5	(60.5-138.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

Leukemia

Male	2	2.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Lung and Bronchus

Male	16	12.3	129.9	(74.2-211.0)
Female	11	10.5	104.9	(52.3-187.7)

Thyroid

Male	1	0.8	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	5	5.0	99.7	(32.1-232.6)
--------	---	-----	------	--------------

All Sites / Types

Male	85	88.9	95.6	(76.4-118.2)
Female	68	77.8	87.4	(67.9-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

119

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	2	1.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	7	5.8	120.1	(48.1-247.5)	Female	1	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	5	6.4	78.4	(25.3-183.1)
Male	0	0.1	nc	(nc-nc)	Stomach				
Female	1	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Testis				
Female	1	0.4	nc	(nc-nc)					
Larynx									

Male	0	0.3	nc	(nc-nc)	Male	2	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	19	21.2	89.5	(53.9-139.8)
Female	1	2.4	nc	(nc-nc)	Female	19	18.4	103.5	(62.3-161.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

120

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.0	100.4	(48.1-184.7)	Male	8	5.2	154.9	(66.7-305.3)
Female	4	4.1	nc	(nc-nc)	Female	5	4.4	113.5	(36.6-264.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.9	123.6	(45.1-269.1)
Female	23	36.7	62.7	(39.7-94.1)	Female	4	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
					Female	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	14.7	102.2	(57.2-168.6)	Female	2	4.1	nc	(nc-nc)
Female	15	16.7	90.0	(50.3-148.5)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	36.3	115.6	(83.3-156.2)
Female	0	0.6	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	3.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)

Female	3	2.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	0	1.0	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	6	7.6	79.0	(28.9-172.0)
Male	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.8	nc	(nc-nc)	Male	121	125.7	96.3	(79.9-115.0)
<u>Lung and Bronchus</u>					Female	101	130.7	77.3	(63.0-93.9)
Male	16	18.0	89.1	(50.9-144.6)					
Female	16	18.4	86.9	(49.6-141.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

121

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	22.0	90.8	(55.4-140.2)	Male	5	11.7	42.8	(13.8-99.9)
Female	14	9.3	150.8	(82.4-253.1)	Female	7	10.3	68.0	(27.2-140.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.9	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.9	73.1	(31.5-144.0)
Female	95	82.8	114.7	(92.8-140.2)	Female	11	11.6	95.0	(47.3-169.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	3.5	229.5	(98.8-452.3)	Male	3	7.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	4.2	nc	(nc-nc)
Male	22	32.5	67.7	(42.4-102.5)	<u>Ovary</u>				
Female	35	38.3	91.4	(63.6-127.1)	Female	9	9.2	98.1	(44.7-186.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.4	93.2	(30.0-217.5)	Male	7	6.1	114.7	(45.9-236.3)
Female	2	1.8	nc	(nc-nc)	Female	7	8.1	86.6	(34.7-178.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	63	79.0	79.8	(61.3-102.1)
Female	3	1.4	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	8	8.7	92.5	(39.8-182.2)
Female	2	6.2	nc	(nc-nc)

Larynx

Male	3	3.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)

Leukemia

Male	2	6.8	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	4	4.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)

Lung and Bronchus

Male	35	39.7	88.2	(61.4-122.7)
Female	48	41.3	116.3	(85.8-154.2)

Stomach

Male	4	5.6	nc	(nc-nc)
Female	1	4.3	nc	(nc-nc)

Testis

Male	4	2.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	2.3	nc	(nc-nc)
Female	2	7.9	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	18	16.8	106.9	(63.3-169.0)
--------	----	------	-------	--------------

All Sites / Types

Male	216	278.5	77.6	(67.6-88.6)
Female	302	297.4	101.6	(90.4-113.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton**Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004**

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	7.3	192.7	(105.2-323.3)	Male	6	4.9	122.2	(44.6-265.9)
Female	1	2.4	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.4	160.9	(64.5-331.5)
Female	45	31.8	141.5	(103.2-189.3)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.4	113.9	(60.6-194.9)	Female	0	3.3	nc	(nc-nc)
Female	11	9.5	116.2	(58.0-208.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>									

Male	0	0.8	nc	(nc-nc)	Male	33	30.1	109.8	(75.6-154.2)
Female	0	0.6	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	7	3.6	194.1	(77.8-399.9)	Male	1	1.9	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.8	nc	(nc-nc)	Female	8	6.3	127.3	(54.8-250.8)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	8	13.9	57.7	(24.8-113.6)	Male	106	104.9	101.0	(82.7-122.2)
Female	6	11.9	50.4	(18.4-109.7)	Female	99	97.7	101.3	(82.4-123.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

123

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.8	138.9	(59.8-273.8)	Male	5	3.5	142.4	(45.9-332.3)
Female	1	1.9	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	22	22.6	97.4	(61.0-147.5)	Female	1	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.8	124.7	(62.1-223.1)	Female	5	2.4	211.4	(68.1-493.3)
Female	10	7.4	134.6	(64.4-247.5)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)

Female	0	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.5	nc	(nc-nc)	Male	25	24.0	104.4	(67.5-154.1)
Female	0	0.4	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	1.5	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Testis				
Larynx					Male	1	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Thyroid				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Leukemia					Female	4	2.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	1	1.5	nc	(nc-nc)	Female	8	4.6	174.2	(75.0-343.3)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	1	1.3	nc	(nc-nc)	Male	86	80.5	106.8	(85.5-132.0)
Female	0	0.4	nc	(nc-nc)	Female	73	71.9	101.5	(79.6-127.6)
Lung and Bronchus									
Male	11	11.1	99.1	(49.4-177.2)					
Female	10	9.4	106.3	(50.9-195.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

124

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	5	7.2	69.3	(22.3-161.7)	Male	4	3.6	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	22	24.2	91.0	(57.0-137.7)	Female	9	3.3	270.3	(123.4-513.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.0	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Colon / Rectum					Female	0	1.2	nc	(nc-nc)
Male	8	10.5	75.9	(32.7-149.7)	Ovary				
Female	9	11.0	82.0	(37.4-155.6)	Female	2	2.7	nc	(nc-nc)

Esophagus

Male	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Kidney & Renal Pelvis

Male	3	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)

Larynx

Male	0	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)

Leukemia

Male	1	2.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	1	1.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)

Lung and Bronchus

Male	8	12.9	61.9	(26.7-122.0)
Female	8	12.1	66.2	(28.5-130.5)

Pancreas

Male	3	2.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)

Prostate

Male	25	25.3	98.9	(64.0-146.0)
------	----	------	------	--------------

Stomach

Male	3	1.8	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)

Testis

Male	0	0.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.7	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	1	5.0	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	83	88.9	93.3	(74.3-115.7)
Female	75	86.0	87.2	(68.6-109.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

125

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.1	86.3	(34.6-177.8)	Male	4	4.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	31	31.3	98.9	(67.2-140.4)	Female	6	3.9	155.3	(56.7-338.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	5	3.2	157.9	(50.9-368.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
					Female	0	1.5	nc	(nc-nc)

Male	14	12.2	114.5	(62.5-192.1)					
Female	15	11.5	130.8	(73.1-215.7)					
<u>Esophagus</u>									
Male	2	2.1	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					
<u>Hodgkin Lymphoma</u>									
Male	1	0.7	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>									
Male	3	3.5	nc	(nc-nc)					
Female	6	2.2	271.0	(98.9-589.8)					
<u>Larynx</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)					
<u>Leukemia</u>									
Male	3	2.6	nc	(nc-nc)					
Female	4	2.1	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	1.7	nc	(nc-nc)					
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	15.2	91.9	(50.2-154.2)					
Female	21	14.4	146.3	(90.5-223.6)					
					Female	6	3.3	179.6	(65.6-390.9)
					<u>Pancreas</u>				
					Male	3	2.3	nc	(nc-nc)
					Female	2	2.5	nc	(nc-nc)
					<u>Prostate</u>				
					Male	26	32.6	79.8	(52.1-117.0)
					<u>Stomach</u>				
					Male	3	2.1	nc	(nc-nc)
					Female	2	1.2	nc	(nc-nc)
					<u>Testis</u>				
					Male	0	1.1	nc	(nc-nc)
					<u>Thyroid</u>				
					Male	0	1.0	nc	(nc-nc)
					Female	0	3.4	nc	(nc-nc)
					<u>Uteri Corpus and Uterus, NOS</u>				
					Female	7	6.5	107.3	(43.0-221.1)
					<u>All Sites / Types</u>				
					Male	101	109.4	92.3	(75.2-112.2)
					Female	122	104.0	117.3	(97.4-140.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

126

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.9	nc	(nc-nc)	Male	7	4.7	147.9	(59.3-304.8)
Female	2	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	26	29.2	89.1	(58.2-130.5)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	7	3.2	218.8	(87.7-450.9)

Female	3	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	15	12.0	124.9	(69.9-206.1)	Female	2	3.1	nc	(nc-nc)
Female	15	9.6	155.8	(87.1-256.9)	Pancreas				
Esophagus					Male	0	2.3	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	Female	9	2.1	436.7	(199.3-829.0)
Female	2	0.5	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	26	31.5	82.5	(53.9-120.8)
Male	0	0.7	nc	(nc-nc)	Stomach				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	1.0	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Testis				
Female	2	2.0	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Larynx					Thyroid				
Male	0	1.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	5	2.6	189.3	(61.0-441.7)	Female	5	5.9	84.3	(27.2-196.7)
Female	1	1.9	nc	(nc-nc)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	92	108.1	85.1	(68.6-104.4)
Male	1	1.7	nc	(nc-nc)	Female	97	93.6	103.6	(84.0-126.4)
Female	0	0.5	nc	(nc-nc)					
Lung and Bronchus									
Male	7	14.9	46.9	(18.8-96.6)					
Female	6	12.3	48.8	(17.8-106.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

127

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	5	6.0	83.7	(27.0-195.4)	Male	4	3.4	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	25	22.6	110.7	(71.6-163.4)	Female	2	2.7	nc	(nc-nc)

Cervix Uteri

Female	2	1.0	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	7	9.0	77.4	(31.0-159.5)
------	---	-----	------	--------------

Female	11	8.4	131.4	(65.5-235.1)
--------	----	-----	-------	--------------

Esophagus

Male	1	1.6	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	4	2.7	nc	(nc-nc)
------	---	-----	----	---------

Female	0	1.6	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	0	1.0	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	0	1.9	nc	(nc-nc)
------	---	-----	----	---------

Female	1	1.5	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	0	1.3	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	11	11.3	97.0	(48.3-173.5)
------	----	------	------	--------------

Female	13	10.0	130.5	(69.4-223.1)
--------	----	------	-------	--------------

Oral Cavity & Pharynx

Male	1	2.4	nc	(nc-nc)
------	---	-----	----	---------

Female	2	1.1	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	2	2.4	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	1.7	nc	(nc-nc)
------	---	-----	----	---------

Female	2	1.8	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	22	24.8	88.7	(55.6-134.3)
------	----	------	------	--------------

Stomach

Male	2	1.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.9	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	1	0.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.7	nc	(nc-nc)
------	---	-----	----	---------

Female	3	2.3	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	2	4.7	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	65	81.6	79.7	(61.5-101.5)
------	----	------	------	--------------

Female	74	74.3	99.5	(78.2-125.0)
--------	----	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

128

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.3	139.3	(50.9-303.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	14.0	78.8	(39.3-140.9)
Female	0	0.1	nc	(nc-nc)	Female	13	11.4	113.6	(60.4-194.3)
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	3	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

129

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.9	75.9	(34.6-144.1)	Male	10	7.4	134.7	(64.5-247.7)
Female	8	4.6	172.2	(74.1-339.3)	Female	6	6.4	93.3	(34.1-203.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)

Female	3	2.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	55	52.5	104.7	(78.9-136.3)	Female	7	6.2	112.8	(45.2-232.4)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	2.4	nc	(nc-nc)	Male	5	5.3	94.4	(30.4-220.3)
Colon / Rectum					Female	1	2.4	nc	(nc-nc)
Male	19	18.4	103.3	(62.2-161.3)	Ovary				
Female	19	18.3	103.9	(62.5-162.3)	Female	5	5.6	90.0	(29.0-210.1)
Esophagus					Pancreas				
Male	2	3.3	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	1.1	nc	(nc-nc)	Male	46	51.0	90.2	(66.1-120.4)
Female	0	0.9	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	3.1	nc	(nc-nc)
Male	5	5.6	88.6	(28.6-206.8)	Female	1	1.9	nc	(nc-nc)
Female	8	3.6	222.0	(95.6-437.5)	Testis				
Larynx					Male	4	1.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Thyroid				
Female	1	0.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Leukemia					Female	10	5.7	175.0	(83.8-321.8)
Male	5	4.1	122.4	(39.4-285.6)	Uteri Corpus and Uterus, NOS				
Female	2	3.4	nc	(nc-nc)	Female	11	10.9	100.9	(50.3-180.6)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	1	2.8	nc	(nc-nc)	Male	153	169.1	90.5	(76.7-106.0)
Female	0	1.0	nc	(nc-nc)	Female	172	170.1	101.1	(86.5-117.4)
Lung and Bronchus									
Male	19	22.8	83.2	(50.1-129.9)					
Female	15	22.7	66.0	(36.9-108.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

130

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	11	8.2	134.6	(67.1-240.8)	Male	6	5.2	114.6	(41.8-249.4)
Female	1	2.8	nc	(nc-nc)	Female	5	4.3	115.2	(37.1-268.9)

Brain and Other Nervous System

Male	2	1.9	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)

Breast

Male	0	0.3	nc	(nc-nc)
Female	35	34.4	101.8	(70.9-141.5)

Cervix Uteri

Female	1	1.7	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	21	12.7	164.8	(102.0-251.9)
Female	15	10.8	138.8	(77.6-228.9)

Esophagus

Male	6	2.3	261.9	(95.6-570.0)
Female	0	0.5	nc	(nc-nc)

Hodgkin Lymphoma

Male	1	0.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	4.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)

Larynx

Male	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)

Leukemia

Male	3	2.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	3	1.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)

Lung and Bronchus

Male	23	15.9	144.5	(91.5-216.8)
Female	25	14.0	179.0	(115.8-264.3)

Multiple Myeloma

Male	6	1.3	461.8	(168.6-1005.2)
Female	0	0.9	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	6	4.6	129.0	(47.1-280.9)
Female	2	3.9	nc	(nc-nc)

Oral Cavity & Pharynx

Male	6	3.7	160.5	(58.6-349.4)
Female	2	1.6	nc	(nc-nc)

Ovary

Female	4	3.6	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	2.4	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)

Prostate

Male	28	35.8	78.1	(51.9-112.9)
------	----	------	------	--------------

Stomach

Male	2	2.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)

Testis

Male	2	1.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	2	1.2	nc	(nc-nc)
Female	7	4.1	170.7	(68.4-351.8)

Uteri Corpus and Uterus, NOS

Female	8	7.1	111.9	(48.2-220.6)
--------	---	-----	-------	--------------

All Sites / Types

Male	142	118.4	120.0	(101.0-141.4)
Female	122	108.1	112.8	(93.7-134.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	4	2.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	10	10.4	96.5	(46.2-177.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.3	116.4	(37.5-271.7)	Female	1	1.1	nc	(nc-nc)
Female	5	4.1	121.1	(39.0-282.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	11.2	71.4	(30.7-140.7)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	39	38.1	102.3	(72.7-139.8)
Male	0	0.6	nc	(nc-nc)	Female	38	35.4	107.4	(76.0-147.4)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	5.4	149.3	(64.3-294.1)					
Female	2	4.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	105.5	(38.5-229.6)	Male	6	3.9	152.7	(55.8-332.4)
Female	1	1.5	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	18	20.8	86.4	(51.2-136.6)	Female	0	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	9.1	121.4	(60.5-217.2)	Female	5	2.1	235.1	(75.7-548.5)
Female	6	5.9	101.8	(37.2-221.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	29	25.2	115.2	(77.2-165.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	2.9	171.3	(55.2-399.8)	Male	2	1.5	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.5	nc	(nc-nc)	Female	10	4.3	230.4	(110.3-423.8)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	12	11.0	109.0	(56.3-190.4)	Male	96	84.4	113.8	(92.1-138.9)
Female	6	7.8	77.4	(28.3-168.5)	Female	61	62.1	98.2	(75.1-126.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	26.1	118.8	(80.7-168.6)	Male	18	11.9	151.5	(89.7-239.4)
Female	12	9.8	122.0	(63.0-213.1)	Female	11	9.3	118.7	(59.2-212.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	6	3.7	160.6	(58.7-349.6)
Female	6	3.3	184.0	(67.2-400.6)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.5	121.9	(66.6-204.6)
Female	77	79.6	96.7	(76.3-120.8)	Female	7	11.7	60.1	(24.1-123.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	7	7.6	92.0	(36.9-189.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	37.2	67.2	(43.5-99.2)	Female	4	8.9	nc	(nc-nc)
Female	42	39.2	107.2	(77.3-145.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.0	114.2	(49.2-225.0)
Male	7	6.0	116.0	(46.5-239.1)	Female	9	8.5	106.2	(48.5-201.6)
Female	0	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	107	91.7	116.6	(95.6-141.0)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	6.5	77.4	(25.0-180.7)
<u>Kidney & Renal Pelvis</u>					Female	2	4.3	nc	(nc-nc)
Male	11	9.2	119.6	(59.6-214.0)	<u>Testis</u>				
Female	7	6.3	110.6	(44.3-227.8)	Male	6	1.5	408.7	(149.2-889.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	6.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	7.1	84.3	(30.8-183.5)	Female	22	16.8	131.1	(82.2-198.6)
Female	5	6.3	79.8	(25.7-186.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	317	312.0	101.6	(90.7-113.4)
Male	3	4.4	nc	(nc-nc)	Female	267	295.1	90.5	(80.0-102.0)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	46.7	66.3	(45.1-94.1)					
Female	38	44.5	85.4	(60.4-117.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.5	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	21	15.9	132.4	(81.9-202.5)	Female	1	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	5	1.7	288.0	(92.8-672.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	6.8	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.3	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	17.9	100.3	(59.4-158.5)
Male	3	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.7	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	57	59.8	95.4	(72.2-123.5)
Male	0	0.9	nc	(nc-nc)	Female	52	53.6	97.0	(72.5-127.2)
Female	0	0.3	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	7	8.5	82.4	(33.0-169.7)	<u>Lung and Bronchus</u>				
Female	7	7.5	92.7	(37.1-191.1)	<u>Lung and Bronchus</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

135

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	56.4	72.6	(52.1-98.6)	Male	18	32.3	55.7	(33.0-88.0)
Female	18	23.2	77.6	(46.0-122.7)	Female	17	29.5	57.5	(33.5-92.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.5	87.0	(41.7-160.1)	Male	4	8.6	nc	(nc-nc)
Female	10	10.3	97.1	(46.5-178.6)	Female	6	7.3	81.8	(29.9-178.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	23	29.7	77.5	(49.1-116.3)
Female	213	227.8	93.5	(81.4-107.0)	Female	33	30.0	110.0	(75.7-154.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	10.7	103.3	(51.5-184.8)	Male	20	21.1	94.9	(58.0-146.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	78	84.3	92.5	(73.1-115.5)	Female	20	24.8	80.7	(49.3-124.6)
Female	95	93.4	101.7	(82.3-124.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	17	14.2	119.6	(69.6-191.5)	Male	179	212.2	84.4	(72.4-97.7)
Female	11	4.5	243.5	(121.4-435.7)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	5.0	nc	(nc-nc)	Male	8	9.2	87.0	(37.5-171.5)
Female	7	4.5	154.2	(61.8-317.8)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	23.7	118.3	(78.6-171.0)	Female	56	46.3	120.8	(91.3-156.9)
Female	10	16.5	60.6	(29.0-111.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	9.2	98.1	(44.8-186.2)	Male	658	744.0	88.4	(81.8-95.5)
Female	5	2.8	179.6	(57.9-419.1)	Female	735	788.6	93.2	(86.6-100.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	18.6	102.1	(61.4-159.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	17.0	70.4	(36.4-123.1)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	11.5	104.7	(54.0-182.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	95	103.5	91.8	(74.3-112.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	99	107.0	92.5	(75.2-112.7)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

136

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	8	7.5	106.7	(46.0-210.3)
Male	0	0.1	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

137

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	12.3	89.2	(44.5-159.7)
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	1.7	nc	(nc-nc)					

Female 0 1.2 nc (nc-nc)

Female 6 9.3 64.2 (23.4-139.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

138

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	23.0	60.8	(33.2-102.0)	Male	25	13.0	192.4	(124.5-284.0)
Female	15	9.0	166.5	(93.1-274.6)	Female	22	11.1	199.1	(124.7-301.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.5	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	18	11.8	152.2	(90.2-240.5)
Female	107	92.8	115.3	(94.5-139.3)	Female	10	11.5	86.9	(41.6-159.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	4	9.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	4.5	112.1	(36.1-261.5)
Male	32	34.8	91.9	(62.8-129.7)	<u>Ovary</u>				
Female	27	35.7	75.7	(49.9-110.1)	Female	7	9.9	70.4	(28.2-145.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.1	131.7	(56.7-259.5)	Male	3	6.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	5	7.6	65.7	(21.2-153.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	94	94.7	99.3	(80.2-121.5)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.8	nc	(nc-nc)
Male	7	10.1	69.2	(27.7-142.7)	Female	0	3.8	nc	(nc-nc)
Female	9	6.6	137.0	(62.5-260.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.6	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.2	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.1	110.4	(52.9-203.1)
Male	10	7.3	137.0	(65.6-252.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.3	nc	(nc-nc)	Female	18	19.5	92.4	(54.7-146.1)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	2	4.9	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

Lung and Bronchus

Male	21	43.7	48.1	(29.8-73.5)
Female	32	42.6	75.1	(51.4-106.0)

All Sites / Types

Male	274	312.0	87.8	(77.7-98.8)
Female	307	310.2	99.0	(88.2-110.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

139

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	6	6.9	86.3	(31.5-187.9)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	6	2.4	254.5	(92.9-554.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	0.5	nc	(nc-nc)	Male	13	8.3	157.3	(83.7-269.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Larynx</u>									
Male	1	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									

Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	3.7	nc	(nc-nc)	Male	36	26.9	133.9	(93.8-185.4)
Female	5	3.0	164.5	(53.0-383.8)	Female	32	22.4	142.7	(97.6-201.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

140

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	13.2	68.4	(31.2-129.9)	Male	4	7.1	nc	(nc-nc)
Female	6	4.7	126.9	(46.3-276.2)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.6	nc	(nc-nc)
Female	47	46.8	100.3	(73.7-133.4)	Female	5	6.0	83.4	(26.9-194.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	4.8	104.7	(33.7-244.3)
					Female	5	2.3	217.4	(70.1-507.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	19.5	66.7	(35.5-114.0)	Female	5	5.0	99.1	(31.9-231.2)
Female	11	18.1	60.7	(30.3-108.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.7	nc	(nc-nc)
Male	5	3.3	150.1	(48.4-350.3)	Female	3	4.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	52.0	71.1	(50.1-98.0)
Male	4	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	3.3	181.9	(66.4-395.8)
<u>Kidney & Renal Pelvis</u>					Female	4	1.9	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	2.2	230.7	(74.4-538.4)	Male	2	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)					
<u>Leukemia</u>									
Male	3	4.1	nc	(nc-nc)					

Female 5 3.2 154.9 (49.9-361.5)

Liver and Intrahepatic Bile Ducts

Male 5 2.6 189.9 (61.2-443.3)

Female 1 0.9 nc (nc-nc)

Lung and Bronchus

Male 29 24.8 116.9 (78.3-167.9)

Female 28 23.0 121.6 (80.8-175.8)

Female 3 4.7 nc (nc-nc)

Uteri Corpus and Uterus, NOS

Female 11 9.9 111.6 (55.7-199.8)

All Sites / Types

Male 148 173.4 85.4 (72.2-100.3)

Female 156 159.6 97.7 (83.0-114.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

141

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	18.8	90.6	(52.8-145.1)	Male	11	10.5	104.7	(52.2-187.3)
Female	6	6.6	90.4	(33.0-196.7)	Female	6	8.4	71.7	(26.2-156.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	5	2.9	174.4	(56.2-407.1)
Female	4	2.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.6	103.7	(49.7-190.8)
Female	73	69.0	105.7	(82.9-133.0)	Female	7	8.6	81.4	(32.6-167.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	5	7.3	68.2	(22.0-159.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	28.3	63.7	(37.7-100.7)	Female	12	7.4	162.5	(83.9-283.8)
Female	21	26.5	79.3	(49.0-121.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.4	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	1	5.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	74.3	72.7	(54.6-94.8)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.8	nc	(nc-nc)
Male	2	8.0	nc	(nc-nc)	<u>Testis</u>				
Female	3	4.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Larynx</u>									
Male	3	3.2	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

Leukemia

Male	10	5.9	168.9	(80.9-310.6)
Female	3	4.7	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	3	3.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)

Lung and Bronchus

Male	25	35.0	71.4	(46.2-105.4)
Female	23	31.5	73.0	(46.2-109.5)

Thyroid

Male	5	2.2	228.4	(73.6-533.1)
Female	7	7.0	100.0	(40.1-206.0)

Uteri Corpus and Uterus, NOS

Female	16	14.2	112.3	(64.1-182.4)
--------	----	------	-------	--------------

All Sites / Types

Male	198	250.1	79.2	(68.5-91.0)
Female	211	230.8	91.4	(79.5-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

142

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	6	2.2	278.6	(101.7-606.5)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	9	3.4	267.0	(121.9-506.9)	Female	1	0.8	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Pancreas				
Esophagus					Male	0	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	9	9.0	99.5	(45.4-188.9)
Male	0	0.2	nc	(nc-nc)	Stomach				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Testis				
Female	1	0.5	nc	(nc-nc)					
Larynx									

Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	4.1	nc	(nc-nc)	Male	34	30.8	110.5	(76.5-154.4)
Female	6	3.0	198.0	(72.3-431.1)	Female	25	24.2	103.2	(66.8-152.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

143

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	11.9	143.1	(83.3-229.1)	Male	12	7.6	157.0	(81.0-274.3)
Female	5	4.1	123.4	(39.8-288.1)	Female	10	6.3	158.0	(75.6-290.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	5	1.9	264.0	(85.1-616.0)
Female	1	2.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.8	88.7	(32.4-193.1)
Female	63	51.5	122.4	(94.0-156.6)	Female	3	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	2.5	241.9	(88.3-526.5)	Male	9	5.5	162.9	(74.3-309.3)
Female	6	2.5	241.9	(88.3-526.5)	Female	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	18.6	118.6	(74.3-179.5)	Female	4	5.3	nc	(nc-nc)
Female	11	15.6	70.5	(35.1-126.1)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	6	3.6	168.8	(61.6-367.4)
Female	2	0.8	nc	(nc-nc)	Female	6	3.3	180.5	(65.9-393.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	65	52.3	124.3	(95.9-158.4)
Female	1	0.9	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	5	5.8	85.8	(27.6-200.2)	Male	4	3.1	nc	(nc-nc)

Female	3	3.4	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	2.2	nc	(nc-nc)	Male	5	1.9	259.0	(83.5-604.3)
Female	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male	1	1.8	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	Female	5	6.0	83.8	(27.0-195.5)
Female	1	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female	11	10.6	103.6	(51.7-185.4)
Male	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	0.8	nc	(nc-nc)	Male	208	172.3	120.7	(104.9-138.3)
<u>Lung and Bronchus</u>					Female	163	159.0	102.5	(87.4-119.5)
Male	25	23.2	107.9	(69.8-159.4)					
Female	13	20.5	63.6	(33.8-108.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

144

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	43.5	94.3	(67.6-127.9)	Male	16	22.8	70.3	(40.1-114.1)
Female	13	17.7	73.5	(39.1-125.6)	Female	25	20.3	123.3	(79.8-182.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	8.0	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	5	7.3	68.6	(22.1-160.0)	Female	3	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	15	21.5	69.9	(39.1-115.3)
Female	133	158.7	83.8	(70.1-99.3)	Female	20	22.1	90.3	(55.2-139.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	6.9	144.5	(69.2-265.8)	Male	17	14.7	115.6	(67.3-185.1)
<u>Colon / Rectum</u>					Female	6	8.2	73.4	(26.8-159.8)
Male	60	63.8	94.0	(71.8-121.1)	<u>Ovary</u>				
Female	70	72.0	97.2	(75.8-122.9)	Female	15	17.6	85.0	(47.5-140.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.5	132.9	(72.6-222.9)	Male	11	12.0	91.6	(45.7-163.9)
Female	3	3.4	nc	(nc-nc)	Female	15	15.3	98.1	(54.9-161.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.3	nc	(nc-nc)	Male	139	157.6	88.2	(74.1-104.1)
Female	1	3.1	nc	(nc-nc)					

Kidney & Renal Pelvis

Male	9	17.0	53.0	(24.2-100.6)
Female	12	12.0	100.3	(51.8-175.2)

Larynx

Male	7	6.7	104.1	(41.7-214.5)
Female	2	2.0	nc	(nc-nc)

Leukemia

Male	15	13.8	109.0	(61.0-179.8)
Female	11	12.7	86.4	(43.0-154.5)

Liver and Intrahepatic Bile Ducts

Male	7	8.2	85.6	(34.3-176.4)
Female	1	3.6	nc	(nc-nc)

Lung and Bronchus

Male	87	78.7	110.5	(88.5-136.3)
Female	82	79.2	103.6	(82.4-128.6)

Stomach

Male	9	11.0	81.6	(37.2-155.0)
Female	7	8.0	87.5	(35.0-180.2)

Testis

Male	5	5.4	92.7	(29.9-216.4)
------	---	-----	------	--------------

Thyroid

Male	4	4.5	nc	(nc-nc)
Female	11	16.0	68.5	(34.2-122.7)

Uteri Corpus and Uterus, NOS

Female	41	32.6	125.7	(90.2-170.6)
--------	----	------	-------	--------------

All Sites / Types

Male	502	551.1	91.1	(83.3-99.4)
Female	529	571.2	92.6	(84.9-100.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

145

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.0	114.7	(49.4-226.1)	Male	4	3.8	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	24	25.8	93.2	(59.7-138.6)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
					Female	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	10.3	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
Female	9	10.7	84.1	(38.4-159.6)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				

Male	0	0.5	nc	(nc-nc)	Male	21	25.0	83.9	(51.9-128.2)
Female	0	0.4	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	1	2.8	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	6	1.9	321.1	(117.2-698.9)	Female	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	15	12.6	118.8	(66.4-196.0)	Male	74	88.7	83.4	(65.5-104.7)
Female	8	12.2	65.7	(28.3-129.4)	Female	77	88.9	86.6	(68.3-108.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

146

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.2	65.6	(23.9-142.7)	Male	4	6.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	6	5.7	105.9	(38.7-230.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.7	123.4	(49.4-254.3)
Female	45	43.0	104.6	(76.3-140.0)	Female	3	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	14.6	34.4	(11.1-80.2)	Female	6	4.4	135.3	(49.4-294.4)
Female	10	13.3	75.4	(36.1-138.8)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.6	nc	(nc-nc)	Male	7	2.8	254.5	(102.0-524.4)

Female	3	0.6	nc	(nc-nc)	Female	5	2.8	181.3	(58.4-423.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	42	38.1	110.1	(79.4-148.9)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.4	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.1	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.7	nc	(nc-nc)
Male	6	3.5	170.4	(62.2-370.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	5	8.3	60.2	(19.4-140.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.3	nc	(nc-nc)	Male	118	134.7	87.6	(72.5-104.9)
Female	0	0.7	nc	(nc-nc)	Female	122	133.5	91.4	(75.9-109.1)
<u>Lung and Bronchus</u>									
Male	14	17.5	79.9	(43.6-134.1)					
Female	14	16.0	87.3	(47.7-146.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

147

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	2.8	211.4	(77.2-460.1)	Male	1	2.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	12	12.3	97.9	(50.5-171.0)	Female	2	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)

Esophagus

Male	3	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Kidney & Renal Pelvis

Male	2	1.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Larynx

Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)

Leukemia

Male	2	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Lung and Bronchus

Male	3	5.6	nc	(nc-nc)
Female	6	4.5	133.8	(48.9-291.3)

Pancreas

Male	1	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)

Prostate

Male	18	12.4	145.3	(86.1-229.7)
------	----	------	-------	--------------

Stomach

Male	1	0.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)

Testis

Male	0	0.7	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	0	0.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	0	2.4	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	47	42.4	110.7	(81.4-147.3)
Female	40	37.5	106.6	(76.1-145.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

148

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	18.1	110.7	(67.6-170.9)	Male	7	10.9	64.5	(25.8-132.9)
Female	11	6.7	163.5	(81.5-292.5)	Female	11	9.0	121.8	(60.7-218.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.8	157.2	(57.4-342.2)	Male	0	2.8	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.7	92.4	(42.1-175.3)
Female	60	71.8	83.5	(63.7-107.5)	Female	8	8.8	90.5	(39.0-178.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.3	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
					Female	5	3.4	145.9	(47.0-340.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				

Male	34	27.6	123.3	(85.4-172.3)					
Female	27	26.1	103.6	(68.2-150.7)					
<u>Esophagus</u>									
Male	5	4.8	103.6	(33.4-241.8)					
Female	0	1.3	nc	(nc-nc)					
<u>Hodgkin Lymphoma</u>									
Male	1	1.6	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>									
Male	7	8.2	85.5	(34.3-176.2)					
Female	5	5.1	98.5	(31.7-229.9)					
<u>Larynx</u>									
Male	1	3.2	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					
<u>Leukemia</u>									
Male	9	6.0	150.6	(68.7-285.9)					
Female	6	4.8	124.3	(45.4-270.5)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	2	4.0	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	34.5	121.6	(87.6-164.4)					
Female	38	33.0	115.3	(81.6-158.3)					
					Female	9	7.7	117.5	(53.6-223.1)
					<u>Pancreas</u>				
					Male	5	5.2	95.3	(30.7-222.4)
					Female	6	5.6	106.9	(39.0-232.7)
					<u>Prostate</u>				
					Male	61	75.0	81.4	(62.2-104.5)
					<u>Stomach</u>				
					Male	2	4.6	nc	(nc-nc)
					Female	4	2.7	nc	(nc-nc)
					<u>Testis</u>				
					Male	4	2.9	nc	(nc-nc)
					<u>Thyroid</u>				
					Male	1	2.5	nc	(nc-nc)
					Female	3	7.9	nc	(nc-nc)
					<u>Uteri Corpus and Uterus, NOS</u>				
					Female	10	15.0	66.8	(32.0-122.8)
					<u>All Sites / Types</u>				
					Male	235	250.5	93.8	(82.2-106.6)
					Female	231	238.5	96.9	(84.8-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

149

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	12.1	165.6	(101.1-255.8)	Male	13	7.2	181.3	(96.4-310.0)
Female	7	4.1	169.4	(67.9-349.1)	Female	8	5.9	136.1	(58.6-268.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	5	6.4	77.7	(25.0-181.3)
Female	58	48.2	120.3	(91.3-155.5)	Female	7	5.5	126.6	(50.7-260.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
					Male	5	5.0	99.2	(32.0-231.4)

Female	1	2.2	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	22	18.5	119.0	(74.6-180.2)	Female	9	5.1	178.1	(81.3-338.2)
Female	20	15.9	126.0	(76.9-194.6)	Pancreas				
Esophagus					Male	0	3.5	nc	(nc-nc)
Male	5	3.2	154.2	(49.7-359.9)	Female	3	3.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Prostate				
Hodgkin Lymphoma					Male	59	50.8	116.1	(88.4-149.8)
Male	1	1.0	nc	(nc-nc)	Stomach				
Female	1	0.8	nc	(nc-nc)	Male	6	3.1	193.3	(70.6-420.7)
Kidney & Renal Pelvis					Female	3	1.6	nc	(nc-nc)
Male	7	5.5	127.7	(51.2-263.1)	Testis				
Female	5	3.3	153.8	(49.6-359.0)	Male	1	1.7	nc	(nc-nc)
Larynx					Thyroid				
Male	5	2.1	233.5	(75.2-544.9)	Male	3	1.6	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	7	5.3	132.4	(53.0-272.8)
Leukemia					Uteri Corpus and Uterus, NOS				
Male	8	3.9	206.1	(88.7-406.1)	Female	10	10.2	98.4	(47.1-181.0)
Female	5	2.9	169.8	(54.7-396.1)	All Sites / Types				
Liver and Intrahepatic Bile Ducts					Male	209	167.5	124.8	(108.4-142.9)
Male	4	2.7	nc	(nc-nc)	Female	204	153.5	132.9	(115.3-152.4)
Female	1	0.8	nc	(nc-nc)					
Lung and Bronchus									
Male	26	23.1	112.3	(73.4-164.6)					
Female	45	20.7	217.3	(158.5-290.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

150

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	5	2.0	244.9	(78.9-571.4)	Male	0	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	12	7.9	152.8	(78.9-266.9)	Female	1	0.9	nc	(nc-nc)

Cervix Uteri

Female	1	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	4	3.2	nc	(nc-nc)
------	---	-----	----	---------

Female	0	2.7	nc	(nc-nc)
--------	---	-----	----	---------

Esophagus

Male	3	0.6	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Hodgkin Lymphoma

Male	0	0.2	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.2	nc	(nc-nc)
--------	---	-----	----	---------

Kidney & Renal Pelvis

Male	1	1.0	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.5	nc	(nc-nc)
--------	---	-----	----	---------

Larynx

Male	0	0.4	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Leukemia

Male	0	0.7	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.5	nc	(nc-nc)
--------	---	-----	----	---------

Liver and Intrahepatic Bile Ducts

Male	0	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.1	nc	(nc-nc)
--------	---	-----	----	---------

Lung and Bronchus

Male	4	3.9	nc	(nc-nc)
------	---	-----	----	---------

Female	5	3.3	150.1	(48.4-350.2)
--------	---	-----	-------	--------------

Oral Cavity & Pharynx

Male	0	0.9	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.4	nc	(nc-nc)
--------	---	-----	----	---------

Ovary

Female	1	0.8	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	0.6	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.6	nc	(nc-nc)
--------	---	-----	----	---------

Prostate

Male	5	8.7	57.4	(18.5-134.1)
------	---	-----	------	--------------

Stomach

Male	1	0.5	nc	(nc-nc)
------	---	-----	----	---------

Female	0	0.3	nc	(nc-nc)
--------	---	-----	----	---------

Testis

Male	0	0.3	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	0.3	nc	(nc-nc)
------	---	-----	----	---------

Female	1	0.9	nc	(nc-nc)
--------	---	-----	----	---------

Uteri Corpus and Uterus, NOS

Female	2	1.6	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	28	29.0	96.6	(64.2-139.7)
------	----	------	------	--------------

Female	30	25.4	118.3	(79.8-168.9)
--------	----	------	-------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

151

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.6	115.4	(68.4-182.4)	Male	12	8.8	136.2	(70.3-238.0)
Female	5	6.3	79.1	(25.5-184.7)	Female	9	7.6	119.2	(54.4-226.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				

Male	0	0.5	nc	(nc-nc)	Male	7	8.0	87.3	(35.0-179.9)
Female	64	62.9	101.7	(78.3-129.9)	Female	5	8.0	62.3	(20.1-145.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	6.1	97.7	(35.7-212.6)
<u>Colon / Rectum</u>					Female	4	3.1	nc	(nc-nc)
Male	20	23.6	84.9	(51.8-131.1)	<u>Ovary</u>				
Female	34	25.3	134.6	(93.2-188.1)	Female	7	6.8	103.2	(41.3-212.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.1	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	68	62.6	108.6	(84.3-137.7)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	12	6.8	176.9	(91.3-309.1)	Female	3	2.7	nc	(nc-nc)
Female	0	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.8	330.4	(120.6-719.1)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.1	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.4	137.0	(50.0-298.3)	Female	15	13.1	114.8	(64.2-189.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.3	nc	(nc-nc)	Male	208	209.3	99.4	(86.3-113.8)
Female	1	1.3	nc	(nc-nc)	Female	220	213.6	103.0	(89.8-117.6)
<u>Lung and Bronchus</u>									
Male	26	29.4	88.3	(57.7-129.4)					
Female	30	29.5	101.5	(68.5-145.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

152

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.1	91.9	(47.5-160.6)	Male	12	7.3	165.5	(85.4-289.1)
Female	13	4.9	267.1	(142.1-456.8)	Female	3	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)

Female	3	2.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	8	6.7	119.3	(51.4-235.1)
Female	47	48.4	97.1	(71.4-129.2)	Female	8	6.3	127.7	(55.0-251.7)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.2	nc	(nc-nc)	Male	5	4.8	103.8	(33.5-242.3)
Colon / Rectum					Female	4	2.4	nc	(nc-nc)
Male	19	19.5	97.7	(58.8-152.5)	Ovary				
Female	17	19.6	86.5	(50.4-138.6)	Female	8	5.2	152.7	(65.8-300.9)
Esophagus					Pancreas				
Male	2	3.3	nc	(nc-nc)	Male	8	3.7	218.2	(93.9-429.9)
Female	1	0.9	nc	(nc-nc)	Female	6	4.2	144.2	(52.7-314.0)
Hodgkin Lymphoma					Prostate				
Male	0	1.0	nc	(nc-nc)	Male	41	48.9	83.9	(60.2-113.8)
Female	0	0.9	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	3	3.3	nc	(nc-nc)
Male	9	5.4	166.3	(75.9-315.7)	Female	4	2.2	nc	(nc-nc)
Female	7	3.5	201.5	(80.7-415.2)	Testis				
Larynx					Male	1	1.7	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	Thyroid				
Female	1	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Leukemia					Female	8	5.2	154.4	(66.5-304.3)
Male	2	4.2	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Female	2	3.6	nc	(nc-nc)	Female	4	9.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					All Sites / Types				
Male	2	2.6	nc	(nc-nc)	Male	179	170.1	105.2	(90.4-121.8)
Female	0	1.0	nc	(nc-nc)	Female	175	165.9	105.5	(90.5-122.4)
Lung and Bronchus									
Male	32	24.0	133.5	(91.3-188.5)					
Female	20	22.4	89.4	(54.6-138.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

153 Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
Bladder, Urinary					Melanoma of Skin				
Male	11	9.8	112.3	(56.0-201.0)	Male	5	5.9	84.7	(27.3-197.8)
Female	3	3.7	nc	(nc-nc)	Female	5	5.0	100.5	(32.4-234.5)

Brain and Other Nervous System

Male	4	2.1	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)

Breast

Male	0	0.3	nc	(nc-nc)
Female	30	39.5	76.0	(51.3-108.6)

Cervix Uteri

Female	0	1.9	nc	(nc-nc)
--------	---	-----	----	---------

Colon / Rectum

Male	16	14.9	107.2	(61.2-174.1)
Female	11	14.9	73.9	(36.8-132.2)

Esophagus

Male	0	2.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Hodgkin Lymphoma

Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)

Kidney & Renal Pelvis

Male	4	4.4	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)

Larynx

Male	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Leukemia

Male	1	3.3	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)

Liver and Intrahepatic Bile Ducts

Male	2	2.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)

Lung and Bronchus

Male	20	18.4	108.4	(66.2-167.4)
Female	17	17.2	98.8	(57.5-158.1)

Multiple Myeloma

Male	0	1.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)

Non-Hodgkin Lymphoma

Male	2	5.3	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)

Oral Cavity & Pharynx

Male	9	4.1	221.1	(100.9-419.7)
Female	1	1.9	nc	(nc-nc)

Ovary

Female	0	4.2	nc	(nc-nc)
--------	---	-----	----	---------

Pancreas

Male	0	2.8	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)

Prostate

Male	35	39.8	88.0	(61.3-122.4)
------	----	------	------	--------------

Stomach

Male	3	2.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)

Testis

Male	3	1.5	nc	(nc-nc)
------	---	-----	----	---------

Thyroid

Male	1	1.3	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	8	8.0	100.2	(43.1-197.4)
--------	---	-----	-------	--------------

All Sites / Types

Male	125	134.8	92.8	(77.2-110.5)
Female	101	131.2	77.0	(62.7-93.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				

Male	5	5.6	90.0	(29.0-210.1)	Male	8	3.8	210.9	(90.8-415.7)
Female	5	2.0	253.7	(81.8-592.0)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	25	20.6	121.1	(78.4-178.8)	Female	0	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	10	8.7	115.6	(55.3-212.5)	<u>Ovary</u>				
Female	7	7.9	88.7	(35.5-182.7)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	24	22.8	105.3	(67.4-156.6)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	2.4	252.5	(92.2-549.7)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.5	nc	(nc-nc)	Female	7	4.2	166.2	(66.6-342.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	91	80.0	113.8	(91.6-139.7)
Female	0	0.4	nc	(nc-nc)	Female	78	69.4	112.4	(88.8-140.2)
<u>Lung and Bronchus</u>									
Male	14	10.5	133.4	(72.9-223.8)					
Female	11	9.1	120.3	(60.0-215.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.5	141.4	(45.6-330.1)	Male	4	2.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	20	12.1	165.6	(101.1-255.7)	Female	3	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	6	4.2	141.7	(51.7-308.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	17	14.4	117.7	(68.6-188.5)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	5	2.5	200.3	(64.6-467.5)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	1	1.1	nc	(nc-nc)	Male	5	6.7	74.5	(24.0-173.8)
Female	0	0.8	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.8	nc	(nc-nc)					
Female	1	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	53.1	84.7	(61.8-113.4)	Male	14	32.4	43.3	(23.6-72.6)
Female	25	21.7	115.1	(74.5-170.0)	Female	10	30.8	32.5	(15.5-59.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.7	110.0	(60.1-184.6)	Male	6	8.1	73.7	(26.9-160.4)
Female	11	11.2	98.0	(48.8-175.3)	Female	3	6.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.6	nc	(nc-nc)	Male	25	29.6	84.4	(54.6-124.6)
Female	166	224.3	74.0	(63.2-86.1)	Female	35	29.1	120.3	(83.8-167.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	11.3	185.7	(114.9-283.8)	Male	29	20.7	140.2	(93.8-201.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	77	80.1	96.1	(75.8-120.1)	Female	19	24.5	77.5	(46.7-121.1)
Female	78	87.4	89.3	(70.6-111.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	15.1	152.7	(96.8-229.1)
Male	14	13.6	103.3	(56.4-173.3)	Female	18	18.5	97.4	(57.7-154.0)
Female	6	4.2	142.3	(52.0-309.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	195	201.8	96.6	(83.5-111.2)
Male	5	6.3	79.6	(25.7-185.8)	<u>Stomach</u>				
Female	5	5.7	87.8	(28.3-204.9)	Male	15	13.8	108.7	(60.8-179.3)
<u>Kidney & Renal Pelvis</u>					Female	4	9.5	nc	(nc-nc)
Male	14	23.1	60.5	(33.1-101.5)	<u>Testis</u>				
Female	9	16.1	55.8	(25.5-106.0)	Male	5	11.7	42.9	(13.8-100.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	8.8	102.5	(46.8-194.6)	Male	3	7.6	nc	(nc-nc)
Female	5	2.7	185.6	(59.8-433.2)	Female	17	28.1	60.4	(35.2-96.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	19.6	92.0	(54.5-145.5)	Female	47	45.4	103.6	(76.1-137.8)
Female	18	17.6	102.3	(60.6-161.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	693	721.9	96.0	(89.0-103.4)
Male	14	11.2	125.1	(68.3-209.9)	Female	653	771.3	84.7	(78.3-91.4)
Female	4	4.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	117	97.8	119.6	(98.9-143.3)					
Female	88	100.9	87.2	(69.9-107.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.6	nc	(nc-nc)	Male	9	4.1	218.3	(99.6-414.4)
Female	0	2.8	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	23	26.9	85.5	(54.2-128.3)	Female	5	3.5	143.3	(46.2-334.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	11.4	166.6	(100.3-260.3)	Female	1	2.9	nc	(nc-nc)
Female	21	10.8	194.4	(120.3-297.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	1.9	nc	(nc-nc)	Male	25	30.1	83.0	(53.7-122.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.2	157.9	(50.9-368.4)	Female	9	5.6	159.7	(72.9-303.2)
Female	0	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	1	2.3	nc	(nc-nc)	Male	15	14.4	104.4	(58.4-172.3)
Female	2	1.9	nc	(nc-nc)	Female	17	13.1	129.4	(75.4-207.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;

- nc = The SIR and 95% CI were not calculated when Obs < 5;

158

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.5	123.9	(65.9-211.9)	Male	3	6.1	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	43	40.0	107.5	(77.8-144.8)	Female	6	5.0	119.0	(43.5-259.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	15.8	95.2	(53.2-156.9)	Female	4	4.3	nc	(nc-nc)
Female	16	15.3	104.5	(59.7-169.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.7	nc	(nc-nc)	Male	36	40.8	88.2	(61.8-122.1)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	8	8.2	97.6	(42.0-192.4)
Female	0	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	3	1.8	nc	(nc-nc)	Male	126	140.5	89.7	(74.7-106.8)
Female	0	0.5	nc	(nc-nc)	Female	136	134.9	100.8	(84.6-119.2)
<u>Leukemia</u>					<u>Male</u>				
Male	4	3.4	nc	(nc-nc)	<u>Female</u>				
Female	2	2.8	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	1	2.2	nc	(nc-nc)	<u>Male</u>				
Female	0	0.8	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	18	19.5	92.4	(54.8-146.1)	<u>Female</u>				
Female	29	18.3	158.6	(106.2-227.7)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

159

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.6	127.6	(63.6-228.3)	Male	6	4.2	143.7	(52.5-312.7)
Female	1	3.6	nc	(nc-nc)	Female	9	3.5	257.2	(117.4-488.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.0	176.5	(70.7-363.6)
Female	26	29.8	87.3	(57.0-127.9)	Female	5	4.3	116.4	(37.5-271.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	12.5	88.1	(43.9-157.7)	Female	3	3.3	nc	(nc-nc)
Female	18	14.7	122.1	(72.3-193.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	30.7	65.2	(39.8-100.7)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	5	6.2	80.7	(26.0-188.3)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	92	105.2	87.5	(70.5-107.3)
Male	1	1.5	nc	(nc-nc)	Female	96	109.3	87.8	(71.2-107.3)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	15.2	85.4	(45.5-146.1)					
Female	11	15.6	70.6	(35.2-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

160

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2000-2004

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	41.7	86.3	(60.5-119.5)	Male	15	23.8	63.0	(35.2-103.9)
Female	18	16.4	110.1	(65.2-173.9)	Female	10	20.9	47.8	(22.9-88.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	8.4	107.1	(48.9-203.4)	Male	4	6.3	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	Female	6	5.2	115.9	(42.3-252.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	28	21.8	128.4	(85.3-185.5)
Female	136	163.0	83.5	(70.0-98.7)	Female	23	21.2	108.7	(68.9-163.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	7.5	79.7	(29.1-173.4)	Male	11	15.8	69.6	(34.7-124.5)
Female					Female	9	8.0	112.4	(51.3-213.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	69	62.5	110.3	(85.9-139.7)	Female	22	17.7	124.6	(78.1-188.7)
Female	69	65.1	106.1	(82.5-134.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	11.8	152.3	(90.2-240.7)
Male	12	10.7	112.5	(58.1-196.6)	Female	14	13.9	100.8	(55.0-169.1)
Female	3	3.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	139	162.5	85.5	(71.9-101.0)
Male	6	3.6	168.1	(61.4-366.0)	<u>Stomach</u>				
Female	2	3.1	nc	(nc-nc)	Male	14	10.6	131.5	(71.8-220.6)
<u>Kidney & Renal Pelvis</u>					Female	16	7.0	227.5	(129.9-369.4)
Male	21	17.8	118.1	(73.1-180.5)	<u>Testis</u>				
Female	12	11.8	101.9	(52.6-177.9)	Male	10	6.4	156.7	(75.0-288.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	6.9	115.5	(49.7-227.6)	Male	4	5.2	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	11	17.8	61.8	(30.8-110.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	13.6	132.3	(78.4-209.1)	Female	28	33.4	83.9	(55.7-121.3)
Female	6	11.8	50.6	(18.5-110.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	560	556.6	100.6	(92.4-109.3)
Male	10	8.6	116.5	(55.8-214.3)					
Female	1	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	78	78.0	100.0	(79.1-124.8)					

Female	64	76.7	83.4	(64.2-106.5)	Female	497	559.2	88.9	(81.2-97.1)
--------	----	------	------	--------------	--------	-----	-------	------	-------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;